Canada markets closed

Telesis Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3090-0.0212 (-6.42%)
At close: 04:00PM EDT
0.3900 +0.08 (+26.21%)
After hours: 07:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3302
Open0.3200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3000 - 0.3499
52 Week Range0.3000 - 3.0100
Volume162,776
Avg. Volume766,336
Market Cap9.302M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-1.6400
Earnings DateMay 10, 2024 - May 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership

    SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA high throughput drug discovery applications and will specifically target the BioXp automation platform on

  • GlobeNewswire

    Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

    SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder

  • GlobeNewswire

    Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

    Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expenseSAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis in their own lab, today announced certain preliminary, unaudited financial results for the fourth quart